Table 3 HDACis in combination with other anticancer agents in phase I/II/III clinical trials

Vorinostat

Sorafenib

AML, APL, MDS

I

Carfilzomib

B-cell lymphoma

I

Zolinza

Lymphoma or Leukemia

I/II

Azacitidine

AML,MDS

II

Temozolomide

AML

II

Rituximab

Lymphoma

II

Decitabine

AML, ALL, CLL, Lymphoma

I

MDS

II

Alisertib

Lymphoma

I

Alvocidib

AML, CML, ALL

I

Isotretinoin

APL,AML, Lymphoma

I

Idarubicin

AML, CML, MDS

I

Idarubicin, Cytarabine

AML, MDS

II

Sorafenib, bortezomib

AML

I/II

Cytarabine, Decitabine

AML, MDS

I

AMG655, Bortezomib

Lymphoma

I

Lenalidomide, Azacitidine

CML, MDS

II

Lenalidomide, Dexamethasone

MM

I

Bortezomib, Dexamethasone

MM

II

Gemtuzumab, Ozogamicin, Azacitidine

AML

I/II

Tacrolimus, Cyclosporine, Methotrexate

CML, AML, Lymphoma

II

Panobinostat

Carfilzomib

MM

I/II

Bortezomib

T-cell lymphoma, MM

II, I

Everolimus

Lymphoma

I/II

Lenalidomide

HL, MM

II, I

Placebo

HL

III

Melphalan

MM

I/II

Cytarabine

Leukemia, NHL

I

5-Azacytidine

AML, MDS, CMML

I

Decitabine

AML, MDS

I/II

Everolimus

Lymphoma

I/II

Imatinib mesylate

Leukemia

I

Lenalidomide, Dexamethasone

MM

II

Carfilzomib, Dexamethasone

MM

I

Bortezomib, Dexamethasone

MM

II

Bortezomib, Placebo

MM

III

Dexamethasone, MLN9708

MM

II

Dexamethasone, Lenalidomide, Bortezomib

MM

I

Cytarabine, Daunorubicin

AML, MDS

I

Ifosfamide, Mesna, Carboplatin, Etoposide, Pegfilgrastim

HL

I/II

Belinostat

Carfilzomib

Peripheral T-cell lymphoma, NHL, DCBCL, FL

I

Rituximab

Lymphoma

II

Idarubicin

AML

I/II

Bortezomib

AML,ALL,MDS,CML

I

VPA

Decitabine

AML, MDS

II

5-azacytidine

AML, MDS

II

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

DLBCL

I/II

Romidepsin

Gemcitabine, dexamethasone and cisplatin

DCBCL

I

5-azacitidine

Relapsed/refractory lymphoid maligancies

I/II

Mocetinostat

Brentuximab vedotin (SGN-35)

HL

I/II

Azacitidine

MDS, AML

I/II

AR42

Decitabine

AML

I

Pomalidomid

MM

I

Entinostat

Sorafenib tosylate

AML

I

4-PBA

Azacitidine

AML, MDS

I

SB939

Azacitidine

Hematologic Malignancies, MDS

I